The OrthoPulse Gen 2 includes new structural and technological improvements over the previous version of the photobiomodulation device.
Ormco Corporation announced that it would be the sole U.S. distributor of the improved OrthoPulse Gen 2 medical device.
Reducing treatment time for patients, OrthoPulse Gen 2 has received structural and technological improvements over the previous version.
OrthoPulse is a clinically proven and FDA-approved medical device using low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement.
It accelerates orthodontic treatment with fixed braces and clear aligners by up to 50%, according to Ormco. The device is designed to be used at home by the patient for ten minutes daily.
OrthoPulse Gen 2 features:
- Increased battery capacity
- Water protecting design in charging case and mouthpiece
- Plastic chassis for flex circuit in mouthpiece help to reduce risk of broken wires
- “Backbone” reinforced on mouthpiece structure
- New version of app includes advanced quality of life updates
“Through modification of a patient’s biological response to treatment and hence shortening the orthodontic timeline, patients and doctors find this device invaluable which is why we are so excited to announce that Ormco is the sole U.S. Distributor for the latest version of the already popular OrthoPulse device,” said Jim McGillivary, president of Ormco. “Giving fixed and aligner patients more comfort2 and significantly lessening treatment time–while shortening chair time and increasing predictive outcomes–are all important aspects of our core business.”
Photo courtesy of Ormco
